BR112018006066A2 - formulação de hipericina para o diagnóstico fotodinâmico - Google Patents

formulação de hipericina para o diagnóstico fotodinâmico

Info

Publication number
BR112018006066A2
BR112018006066A2 BR112018006066-6A BR112018006066A BR112018006066A2 BR 112018006066 A2 BR112018006066 A2 BR 112018006066A2 BR 112018006066 A BR112018006066 A BR 112018006066A BR 112018006066 A2 BR112018006066 A2 BR 112018006066A2
Authority
BR
Brazil
Prior art keywords
photodynamic diagnosis
formulation
hypericin
hypericin formulation
polyvinylpyrrolidone
Prior art date
Application number
BR112018006066-6A
Other languages
English (en)
Inventor
Abrahamsberg Christina
Frantsits Werner
Gerdes Klaus
Gungl József
Kälz Beate
Welzig Stefan
Original Assignee
Sanochemia Pharmazeutika Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanochemia Pharmazeutika Aktiengesellschaft filed Critical Sanochemia Pharmazeutika Aktiengesellschaft
Publication of BR112018006066A2 publication Critical patent/BR112018006066A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0071—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form solution, solute
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/36—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having four or more rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

a presente invenção refere-se a uma formulação, que pode ser usada como fotossensibilizador na detecção precoce de câncer, em particular, câncer de bexiga, contém hipericinato de sódio ligado à polivinilpirrolidona ou complexado com polivinilpirrolidona.
BR112018006066-6A 2015-09-28 2016-04-07 formulação de hipericina para o diagnóstico fotodinâmico BR112018006066A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT6292015 2015-09-28
ATA629/2015 2015-09-28
PCT/AT2016/000034 WO2017054018A1 (de) 2015-09-28 2016-04-07 Formulierung von hypericin zur photodynamischen diagnose

Publications (1)

Publication Number Publication Date
BR112018006066A2 true BR112018006066A2 (pt) 2018-10-09

Family

ID=55854523

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018006066-6A BR112018006066A2 (pt) 2015-09-28 2016-04-07 formulação de hipericina para o diagnóstico fotodinâmico

Country Status (14)

Country Link
US (2) US9629932B2 (pt)
EP (1) EP3237019B1 (pt)
JP (1) JP6800232B2 (pt)
KR (1) KR20180080210A (pt)
CN (1) CN108289967A (pt)
AU (1) AU2016330390B2 (pt)
BR (1) BR112018006066A2 (pt)
CA (1) CA3000419C (pt)
DK (1) DK3237019T3 (pt)
ES (1) ES2762902T3 (pt)
MX (1) MX2018003802A (pt)
PL (1) PL3237019T3 (pt)
RU (1) RU2018114868A (pt)
WO (1) WO2017054018A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108715693B (zh) * 2018-06-29 2020-08-25 南方科技大学 一种光化学除去氧气来保护光敏剂的三重激发态的介质以及方法和应用
EP3593815A1 (de) 2018-07-13 2020-01-15 Planta Naturstoffe Vertriebsges.m.b.h. Hypericin-pvp komplex mit hohem hypericinanteil
WO2022100750A1 (zh) * 2020-11-16 2022-05-19 北京厚燊维康科技有限责任公司 可用于光动力治疗或诊断的制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814014A1 (de) 1997-12-19 1999-09-30 Krewel Meuselbach Gmbh Arzneipflanzentrockenextrakte
DE19756677A1 (de) 1997-12-19 1999-06-24 Krewel Meuselbach Gmbh Arzneipflanzentrockenextrakte
EP1040825A1 (en) * 1999-03-11 2000-10-04 K.U. Leuven Research & Development Means for diagnosing bladder carcinoma
AT408835B8 (de) 2000-05-23 2002-07-25 Andreas Dipl Ing Dr Kubin Präparation von hypericin gebunden an polyvinylpyrrolidon (pvp) verschiedenen polymerisations- und vernetzungsgrades
CN102525937B (zh) * 2012-01-21 2013-07-17 中国农业科学院兰州畜牧与兽药研究所 一种金丝桃素白蛋白纳米粒的制备方法
DE102014204138A1 (de) 2014-03-06 2015-09-24 Briu Gmbh Pharmazeutische Formulierung, Verfahren zur Herstellung der pharmazeutischen Formulierung und Infusionslösung sowie deren Verwendung als Medizinprodukt und/oder als Medikament
US10143751B2 (en) * 2015-09-28 2018-12-04 Sanochemia Pharmazeutika Ag Photodynamic therapy, formulation usable for this purpose, and method for the production and use thereof

Also Published As

Publication number Publication date
JP6800232B2 (ja) 2020-12-16
MX2018003802A (es) 2019-06-24
EP3237019A1 (de) 2017-11-01
US20170196976A1 (en) 2017-07-13
AU2016330390A1 (en) 2018-05-10
US20170087256A1 (en) 2017-03-30
DK3237019T3 (da) 2020-01-13
PL3237019T3 (pl) 2020-04-30
WO2017054018A1 (de) 2017-04-06
CA3000419A1 (en) 2017-04-06
CA3000419C (en) 2021-03-16
CN108289967A (zh) 2018-07-17
ES2762902T3 (es) 2020-05-26
EP3237019B1 (de) 2019-10-09
RU2018114868A3 (pt) 2019-10-28
JP2018534349A (ja) 2018-11-22
US9775900B2 (en) 2017-10-03
RU2018114868A (ru) 2019-10-28
AU2016330390B2 (en) 2019-05-02
US9629932B2 (en) 2017-04-25
KR20180080210A (ko) 2018-07-11

Similar Documents

Publication Publication Date Title
CO2019014414A2 (es) Moléculas de anticuerpo que se unen a cd73 y usos de las mismas
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
BR112017003312A2 (pt) compostos de indazol como inibidores de fgfr quinase, preparação e uso dos mesmos
BR112016025470A2 (pt) ?hdl terapêutico?
CR20150316A (es) Compuestos y sus métodos de empleo
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
NI201500140A (es) Compuestos y composiciones terapéuticos
BR112018003178A2 (pt) absorvente feminino com braçadeiras de barreira
BR112018073642A2 (pt) imunomoduladores para imagiologia tep
UY36178A (es) Novedosos derivados de ácido heteroaril-butanoico
CL2017000053A1 (es) Anticuerpos de unión a protofibrillas aß
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112017018522A2 (pt) composições e métodos para diagnóstico e tratamento do câncer
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
SV2019005822A (es) Metodos para tratar el cáncer de próstata
BR112015017241A8 (pt) composto, composição farmacêutica, uso do composto e da composição farmacêutica e kit
BR112016020260A8 (pt) uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
CR20140400A (es) Terapia combinada para el tratamiento del cancer de ovario
BR112017008481A2 (pt) composto antimicótico
BR112017012005A2 (pt) compostos orgânicos
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: SANOCHEMIA PHARMAZEUTIKA GMBH (AT)